Myriad Genetics (MYGN) 10-Q 8 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 01, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	0-26642
Entity Registrant Name	MYRIAD GENETICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0494517
Entity Address, Address Line One	322 North 2200 West
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84116
City Area Code	801
Local Phone Number	584-3600
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	MYGN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		90,507,981
Amendment Flag	false
Entity Central Index Key	0000899923
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 96.9	$ 132.1
Marketable investment securities	7.4	8.8
Trade accounts receivable	118.1	114.3
Inventory	24.6	22
Prepaid taxes	18.4	17
Prepaid expenses and other current assets	24.9	19.4
Total current assets	290.3	313.6
Operating lease right-of-use assets	58.9	61.6
Property, plant, and equipment, net	118.5	119
Intangibles, net	340.9	349.5
Goodwill	287	287.4
Other assets	14.9	15.4
Total assets	1,110.5	1,146.5
Current liabilities:
Accounts payable	33.1	25.8
Accrued liabilities	99.2	113.9
Current maturities of operating lease liabilities	13.8	16.2
Total current liabilities	146.1	155.9
Unrecognized tax benefits	30.8	30.2
Long-term debt	38.7	38.5
Noncurrent operating lease liabilities	94.3	97.4
Other long-term liabilities	40.6	41.3
Total liabilities	350.5	363.3
Commitments and contingencies
Stockholders’ equity:
Common stock, 90.5 million and 89.9 million shares outstanding at March 31, 2024 and December 31, 2023, respectively	0.9	0.9
Additional paid-in capital	1,418.8	1,415.5
Accumulated other comprehensive loss	(4.2)	(3.7)
Accumulated deficit	(655.5)	(629.5)
Total stockholders' equity	760	783.2
Total liabilities and stockholders’ equity	$ 1,110.5	$ 1,146.5

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - shares shares in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, shares outstanding (shares)	90.5	89.9	81.5	81.2

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Testing revenue	$ 202.2	$ 181.2
Costs and expenses:
Cost of testing revenue	64.6	59.2
Research and development expense	24.9	22.5
Selling, general, and administrative expense	140.6	151.7
Total costs and expenses	230.1	233.4
Operating loss	(27.9)	(52.2)
Other income (expense):
Interest income	0.6	0.7
Interest expense	(0.5)	(0.5)
Other	1.9	(0.6)
Total other income (expense), net	2	(0.4)
Loss before income tax	(25.9)	(52.6)
Income tax expense	0.1	2.1
Net loss	$ (26)	$ (54.7)
Net loss per share:
Basic (dollars per share)	$ (0.29)	$ (0.67)
Diluted (dollars per share)	$ (0.29)	$ (0.67)
Weighted average shares outstanding:
Basic (shares)	89.9	81.3
Diluted (shares)	89.9	81.3
Revenue from contract with customer, product and service, extensible enumeration	Testing [Member]	Testing [Member]
Cost, product and service, extensible enumeration	Testing [Member]	Testing [Member]

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (26)	$ (54.7)
Change in unrealized loss on available-for-sale debt securities, net of tax	0.1	1.2
Change in foreign currency translation adjustment, net of tax	(1.3)	0.3
Reclassification of cumulative translation adjustment to income upon liquidation of an investment in a foreign entity, net of tax	0.7	0
Comprehensive loss	$ (26.5)	$ (53.2)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Millions	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit
Beginning balance at Dec. 31, 2022	$ 885.8	$ 0.8	$ 1,260.1	$ (8.9)	$ (366.2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax	(4.9)		(4.9)
Stock-based payment expense	7.5		7.5
Net loss	(54.7)				(54.7)
Other comprehensive Income (loss) net of tax	1.5			1.5
Ending balance at Mar. 31, 2023	835.2	0.8	1,262.7	(7.4)	(420.9)
Beginning balance at Dec. 31, 2023	783.2	0.9	1,415.5	(3.7)	(629.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax	(8.7)		(8.7)
Stock-based payment expense	12		12
Net loss	(26)				(26)
Other comprehensive Income (loss) net of tax	(0.5)			(0.5)
Ending balance at Mar. 31, 2024	$ 760	$ 0.9	$ 1,418.8	$ (4.2)	$ (655.5)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (26)	$ (54.7)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15.7	19.4
Non-cash lease expense	2.3	2.9
Stock-based compensation expense	12	7.5
Deferred income taxes	0.6	0.1
Unrecognized tax benefits	0.6	1.9
Impairment of goodwill and long-lived assets	1.2	0
Gain on termination of lease	(3.1)	0
Gain on acquisition	(2.2)	0
Other non-cash adjustments	0.9	0.8
Changes in assets and liabilities:
Prepaid expenses and other current assets	(5.2)	(4)
Trade accounts receivable	(3.9)	(17.5)
Inventory	(1.8)	(1.7)
Prepaid taxes	(1.4)	0
Other assets	0.2	(2.3)
Tenant improvement allowance received	0	13.2
Accounts payable	6.1	7.6
Accrued liabilities	(14.7)	(6.5)
Deferred revenues	0.1	0.1
Net cash used in operating activities	(18.6)	(33.2)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	(6.7)	(23.5)
Capitalization of internal-use software costs	(1.9)	0
Proceeds from maturities and sales of marketable investment securities	1.5	58.1
Net cash provided by (used in) investing activities	(7.1)	34.6
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of tax withheld for common stock issued under stock-based compensation plans	(8.7)	(4.9)
Proceeds from revolving credit facility	60	0
Repayment of revolving credit facility	(60)	0
Payment on finance leases	(0.1)	0
Net cash used in financing activities	(8.8)	(4.9)
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash	(0.8)	0.2
Net decrease in cash, cash equivalents, and restricted cash	(35.3)	(3.3)
Cash, cash equivalents, and restricted cash at beginning of the period	140.9	66.4
Cash, cash equivalents, and restricted cash at end of the period	$ 105.6	$ 63.1

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Myriad Genetics, Inc. (together with its subsidiaries, the “Company” or “Myriad”) is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and offers tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. The Company currently operates as a single reporting segment. The Company’s principal executive office is located in Salt Lake City, Utah. The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”). The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. The Company has historically experienced seasonality in its business, particularly in the quarter ended March 31. Due to the annual reset of patient deductibles at the beginning of the year, the Company has historically experienced a decrease in test volumes and reduction in the average revenue per test in the quarter ended March 31. For the quarter ended March 31, 2024 and 2023, the Company did not experience this seasonality impact to the same extent as prior years. Additionally, operating results for the three months ended March 31, 2024 may not necessarily be indicative of results to be expected for any other interim period or for the full year and historical patterns of seasonality may continue in future periods. Recent Accounting Pronouncements In November 2023, the FASB issued accounting standards update ("ASU") 2023-07, which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company for annual reporting periods beginning after December 15, 2023 and for interim periods within fiscal years December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its segment disclosures. In December 2023, the FASB issued ASU 2023-09, which requires enhanced income tax disclosures, including disaggregation of information on the rate reconciliation table and disaggregated information related to income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its income tax disclosures.

REVENUE

REVENUE	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE The Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, Precise Tumor, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results indicates transfer of control for revenue recognition purposes. The following table presents detail regarding the composition of the Company’s total revenue by product type and by geographical region, either U.S. or rest of world (“RoW”): Three months ended March 31, 2024 2023 (in millions) U.S. RoW Total U.S. RoW Total Testing revenues: Hereditary Cancer $ 76.3 $ 11.8 $ 88.1 $ 64.0 $ 11.7 $ 75.7 Tumor Profiling 23.9 7.0 30.9 28.8 8.5 37.3 Prenatal 44.1 0.2 44.3 36.0 0.2 36.2 Pharmacogenomics 38.9 — 38.9 32.0 — 32.0 Total revenue $ 183.2 $ 19.0 $ 202.2 $ 160.8 $ 20.4 $ 181.2 Under ASC 606, Revenue from Contracts with Customers ("ASC 606"), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company’s performance of its contractual obligations. When this occurs, the Company records a contract liability as Deferred revenue, which is included in Accrued liabilities in the Condensed Consolidated Balance Sheets. In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of the Company’s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Cash collections for certain tests delivered may differ from rates estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third-party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the quarter ended March 31, 2024, the Company recognized $3.0 million in revenue due to a retroactive coverage change by a payor for one of its prenatal products. Revenue recognized due to a change in estimate for tests in which the performance obligation was met in prior periods was immaterial. During the three months ended March 31, 2023, the impact of the amounts to be recognized for previously delivered tests was not material to the Company's Condensed Consolidated Statements of Operations. The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented 12% and 11% of total revenue for the three months ended March 31, 2024 and March 31, 2023, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. The Company has only one payor that accounted for more than 10% of accounts receivable at March 31, 2024 and December 31, 2023. The balance of accounts receivable from the payor represented 15% and 12% of the total accounts receivable balance as of March 31, 2024 and December 31, 2023, respectively. The Company does not require collateral from its customers.

MARKETABLE INVESTMENT SECURITIE

MARKETABLE INVESTMENT SECURITIES	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
MARKETABLE INVESTMENT SECURITIES	MARKETABLE INVESTMENT SECURITIES The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for debt securities classified as available-for-sale securities by major security type and class of security at March 31, 2024 and December 31, 2023 were as follows: (in millions) Amortized Gross Gross Estimated March 31, 2024 Cash and cash equivalents: Cash $ 93.1 $ — $ — $ 93.1 Cash equivalents 3.8 — — 3.8 Total cash and cash equivalents 96.9 — — 96.9 Available-for-sale: Corporate bonds and notes 6.9 — (0.1) 6.8 Municipal bonds 0.6 — — 0.6 Federal agency issues — — — — Total $ 104.4 $ — $ (0.1) $ 104.3 (in millions) Amortized Gross Gross Estimated December 31, 2023 Cash and cash equivalents: Cash $ 129.9 $ — $ — $ 129.9 Cash equivalents 2.2 — — 2.2 Total cash and cash equivalents 132.1 — — 132.1 Available-for-sale: Corporate bonds and notes 8.4 — (0.1) 8.3 Municipal bonds 0.5 — — 0.5 Total $ 141.0 $ — $ (0.1) $ 140.9 Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at March 31, 2024: (in millions) Amortized Estimated Cash $ 93.1 $ 93.1 Cash equivalents 3.8 3.8 Available-for-sale: Due within one year 7.5 7.4 Total $ 104.4 $ 104.3 The cost of a security sold, or amount reclassified out of accumulated other comprehensive income or loss into net loss, is determined based on the specific identification method. The Company does not intend to sell these available-for-sale debt securities, and it is not more likely than not that the Company will be required to sell these securities prior to recovery of their amortized cost basis. Additional information relating to fair value of marketable investment securities can be found in Note 4.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration related to the acquisitions of Sividon Diagnostics GmbH ("Sividon") and Gateway Genomics, LLC ("Gateway"), the Company reassesses the fair value of each expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement periods of approximately 11.25 years and 1 year for Sividon and Gateway, respectively, utilizing various potential pay-out scenarios. Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business. The contingent consideration liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets. Changes to contingent consideration liabilities are reflected in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements. The fair value of the Company’s long-term debt, which it considers a Level 2 measurement, is estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements. The fair value of the Company’s long-term debt is estimated to be $39.8 million at March 31, 2024. The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis: (in millions) Level 1 Level 2 Level 3 Total March 31, 2024 Money market funds (a) $ 3.8 $ — $ — $ 3.8 Corporate bonds and notes 1.4 5.4 — 6.8 Municipal bonds — 0.6 — 0.6 Contingent consideration — — (5.4) (5.4) Total $ 5.2 $ 6.0 $ (5.4) $ 5.8 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. (in millions) Level 1 Level 2 Level 3 Total December 31, 2023 Money market funds (a) $ 2.2 $ — $ — $ 2.2 Corporate bonds and notes — 8.3 — 8.3 Municipal bonds — 0.5 — 0.5 Contingent consideration — — (5.4) (5.4) Total $ 2.2 $ 8.8 $ (5.4) $ 5.6 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. The following table reconciles the change in the fair value of the contingent consideration during the periods presented: (in millions) Carrying Balance at December 31, 2023 $ (5.4) Change in fair value recognized in the Statements of Operations 0.2 Translation adjustments recognized in Other comprehensive loss (0.2) Ending balance at March 31, 2024 $ (5.4)

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET The property, plant and equipment at March 31, 2024 and December 31, 2023 were as follows: (in millions) March 31, December 31, Leasehold improvements $ 77.8 $ 91.3 Equipment 151.5 147.6 Property, plant and equipment, gross 229.3 238.9 Less accumulated depreciation (110.8) (119.9) Property, plant and equipment, net $ 118.5 $ 119.0 During the three months ended March 31, 2023, the Company incurred $5.7 million of accelerated depreciation of leasehold improvements and equipment in connection with the Company's decision to cease the use of its corporate headquarters in Salt Lake City and transition corporate support operations to its new facility in west Salt Lake City. The Company formally assigned the previous corporate headquarters lease to a third party as of December 31, 2023. See Note 15 for further discussion. The Company recorded depreciation during the respective periods as follows: Three months ended (in millions) 2024 2023 Depreciation expense $ 4.9 $ 8.7

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The changes in the carrying amount of goodwill for the three months ended March 31, 2024 are as follows: (in millions) Total Beginning balance $ 287.4 Translation adjustments (0.4) Ending balance $ 287.0 Intangible Assets Intangible assets consist of amortizable assets of developed technologies, customer relationships, and trademarks. The following summarizes the amounts reported as intangible assets: (in millions) Gross Accumulated Net At March 31, 2024 Developed technologies $ 625.4 $ (305.4) $ 320.0 Internal-use software 1.6 (0.3) 1.3 Internal-use software (in-process) 13.0 — 13.0 Customer relationships 1.6 (0.2) 1.4 Trademarks 6.1 (0.9) 5.2 Total intangible assets $ 647.7 $ (306.8) $ 340.9 (in millions) Gross Accumulated Net At December 31, 2023 Developed technologies $ 626.1 $ (295.3) $ 330.8 Internal-use software 0.8 (0.1) 0.7 Internal-use software (in-process) 11.2 — 11.2 Customer relationships 1.6 (0.2) 1.4 Trademarks 6.1 (0.7) 5.4 Total intangible assets $ 645.8 $ (296.3) $ 349.5 The Company recorded amortization expense during the respective periods for these intangible assets as follows: Three months ended (in millions) 2024 2023 Amortization of intangible assets $ 10.8 $ 10.7

ACCRUED LIABILITIES

ACCRUED LIABILITIES	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
ACCRUED LIABILITIES	ACCRUED LIABILITIES The Company's accrued liabilities at March 31, 2024 and December 31, 2023 were as follows: (in millions) March 31, December 31, Employee compensation and benefits $ 37.8 $ 49.7 Accrued taxes payable 6.1 4.6 Refunds payable and reserves 19.1 20.1 Short-term contingent consideration 3.0 3.1 Accrued royalties 5.7 5.3 Legal settlement 6.0 6.0 Lease termination accrual 4.4 4.4 Other accrued liabilities 17.1 20.7 Total accrued liabilities $ 99.2 $ 113.9

LONG-TERM DEBT

LONG-TERM DEBT	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT On June 30, 2023, the Company entered into an asset-based revolving credit facility (the “ABL Facility”) with an initial maximum principal amount of $90.0 million, with JPMorgan Chase Bank, N.A. as administrative agent and issuing bank, the other lender parties thereto, and certain of the Company's domestic subsidiaries (the "Guarantors"). On October 31, 2023, the Company entered into an amendment to the ABL Facility to increase the maximum principal amount of the available revolving line of credit by $25.0 million for a total maximum principal commitment of $115.0 million under the ABL Facility, which was effected through a new commitment provided by a new lender, Goldman Sachs Bank USA. The ABL Facility matures on June 30, 2026. The obligations of the Company are guaranteed by the Guarantors, and the ABL Facility is secured by substantially all of the assets of the Company and the Guarantors. The Company had long-term debt of $40.0 million under the ABL Facility at March 31, 2024 and December 31, 2023, net of $1.3 million and $1.5 million of debt issuance costs, respectively. Proceeds from the ABL Facility were or will be used for the working capital needs and general corporate purposes of the Company and its subsidiaries. Availability under the ABL Facility is subject to a borrowing base, which is the lesser of (a) 85% of the Company's and the Guarantor's eligible accounts receivable plus certain cash held in a segregated and fully-blocked account with the administrative agent in an amount up to $20.0 million ("Eligible Cash") minus any reserves established by the administrative agent in accordance with the ABL Facility, and (b) the aggregate amount of cash collections from eligible accounts of the Company and the Guarantors for the 60 consecutive days most recently ended. Subject to certain conditions, the Company can freely withdraw cash from the Eligible Cash account, provided that any reduction in the Eligible Cash amount will have a corresponding reduction in the borrowing base. Loans outstanding under the ABL Facility will bear interest at a rate per annum equal to, at the option of the Company, either (a) the greatest of (i) the daily Prime Rate, (ii) the daily NYFRB Rate plus 0.50%, and (iii) the monthly Adjusted Term SOFR Rate (as defined below) plus 1.00% (the “ABR”) plus an applicable margin ranging from 1.00% to 1.50% depending on the aggregate average unused availability under the ABL Facility during the prior quarter or (b) term SOFR for a tenor of one, three or six months (at the Company’s election) plus 0.10% (the “Adjusted Term SOFR Rate”) plus an applicable margin ranging from 2.00% to 2.50% depending on the average unused availability under the ABL Facility during the prior quarter, with an ABR floor of 1.00% and an Adjusted Term SOFR Rate floor of 0.00%. Under the ABL Facility the undrawn fee ranges from 37.5 to 50 basis points based on the daily amount of the available revolving commitment. The weighted average interest rate for borrowings under the ABL Facility as of March 31, 2024 was 8.71%. The Company may elect to prepay all or any portion of the amounts owed prior to the maturity date without premium or penalty. The ABL Facility is also subject to customary mandatory prepayments with the proceeds of unpermitted indebtedness and upon the occurrence of an over-advance. Voluntary and mandatory prepayments and all other payments of the ABL Facility must be accompanied by payment of accrued interest on the principal amount repaid or prepaid. The ABL Facility contains customary loan terms, interest rates, representations and warranties and affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. Covenants under the ABL Facility limit or restrict the Company and its subsidiaries' ability to incur liens, incur indebtedness, dispose of assets, make investments, make certain restricted payments, merge or consolidate and enter into certain speculative hedging arrangements. The ABL Facility requires the Company and the Guarantors, on a consolidated basis, to maintain minimum liquidity of $60.0 million and minimum availability of $25.0 million at all times before achieving a fixed charge coverage ratio of 1.0 to 1.0 and thereafter, to maintain a fixed charge coverage ratio of 1.0 to 1.0 until achieving availability under the ABL Facility of greater than the greater of (a) $10.6 million and (b) 12.5% of the lesser of the maximum commitment amount and the borrowing base for a period of 30 consecutive days. As of March 31, 2024, availability under the ABL Facility was $41.3 million. In addition, the ABL Facility includes a number of customary events of default. If any event of default occurs (subject, in certain instances, to specified grace periods), the principal, premium, if any, interest and any other monetary obligations on all the then-outstanding amounts under the ABL Facility may become due and payable immediately. Under the terms of the ABL Facility, if (i) an event of default has occurred and is continuing or (ii) availability under the ABL Facility is less than the greater of (a) $12.5 million and (b) 15% of the lesser of the maximum commitment amount and the borrowing base, the Company will become subject to cash dominion, upon which the administrative agent will apply funds credited to a collection account to first prepay any outstanding protective advances, second to prepay any revolving loans and third, to cash collateralize any outstanding letter of credit exposure. Such cash dominion period will end when availability has remained in excess of the greater of (i) $12.5 million and (ii) 15% of the lesser of the maximum commitment amount and the borrowing base for a period of 45 consecutive days and no event of default is continuing.

OTHER LONG-TERM LIABILITIES

OTHER LONG-TERM LIABILITIES	3 Months Ended
	Mar. 31, 2024
Other Liabilities Disclosure [Abstract]
OTHER LONG-TERM LIABILITIES	OTHER LONG-TERM LIABILITIES The Company's other long-term liabilities at March 31, 2024 and December 31, 2023 were as follows: (in millions) March 31, December 31, Contingent consideration $ 2.4 $ 2.3 Escrow liability 7.5 7.5 Legal settlement 24.0 24.0 Other 6.7 7.5 Total other long-term liabilities $ 40.6 $ 41.3 Contingent consideration as of March 31, 2024 consisted of the long-term portion of contingent consideration related to the acquisition of Sividon.

PREFERRED AND COMMON STOCKHOLDE

PREFERRED AND COMMON STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
PREFERRED AND COMMON STOCKHOLDERS' EQUITY	PREFERRED AND COMMON STOCKHOLDERS' EQUITY The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at March 31, 2024. The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 90.5 million shares of common stock issued and outstanding at March 31, 2024. Shares of common stock issued and outstanding Three months ended (in millions) 2024 2023 Beginning common stock issued and outstanding 89.9 81.2 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan 0.6 0.3 Common stock issued and outstanding at end of period 90.5 81.5 Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect. The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations: Three months ended (in millions) 2024 2023 Denominator: Weighted-average shares outstanding used to compute basic EPS 89.9 81.3 Effect of dilutive shares — — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 89.9 81.3 Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows: Three months ended (in millions) 2024 2023 Anti-dilutive options and RSUs excluded from EPS computation 6.3 5.6

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION On November 30, 2017, the Company’s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee (the "CHCC") of the Board of Directors, to make grants of restricted stock and restricted stock unit awards to employees, consultants, and directors. Stockholders have subsequently approved amendments to the 2017 Plan increasing the shares available to grant thereunder, including most recently at the Company's annual meeting of stockholders held on June 1, 2023, when stockholders approved an amendment to the 2017 Plan to increase the aggregate number of shares of common stock available thereunder for the granting of awards by an additional 4.8 million shares. As of March 31, 2024, the Company had 2.5 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. The number of shares, terms, and vesting periods are generally determined by the Company’s Board of Directors or the CHCC on an award-by-award basis. RSUs granted to employees generally vest either ratably over three The performance and market conditions associated with PSU awards granted during the three months ended March 31, 2024 include vesting that is based on revenue targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for the relative total stockholder return metric is January 1, 2024 through December 31, 2026, and the revenue and adjusted earnings per share metrics will be measured based on fiscal year 2026 results. The Company estimates the likelihood of achievement of performance conditions for all PSU awards at the end of each period. To the extent those awards or portions thereof are considered probable of being achieved, such awards or portions thereof are expensed over the performance period. The portion of the awards pertaining to relative total stockholder return represent market conditions and, accordingly, the estimated fair value of such awards are recognized over the performance period. Stock Options A summary of the stock option activity for the three months ended March 31, 2024 is as follows: (number of shares in millions) Number Weighted Options outstanding at December 31, 2023 0.7 $ 13.38 Options outstanding at March 31, 2024 0.7 13.38 Options exercisable at March 31, 2024 0.5 $ 13.38 As of March 31, 2024, there was $0.3 million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of 0.4 years. There were no options granted during the three months ended March 31, 2024. Restricted Stock Units A summary of the RSU awards activity under the Company’s equity plan and inducement awards, including PSU awards, for the three months ended March 31, 2024 is as follows: (number of shares in millions) Number Weighted RSUs unvested and outstanding at December 31, 2023 4.4 $ 24.37 RSUs granted 2.3 22.29 Less: RSUs vested (1.0) 25.18 RSUs canceled (0.1) 26.55 RSUs unvested and outstanding at March 31, 2024 5.6 $ 23.36 Employee Stock Purchase Plan The Company also has an Employee Stock Purchase Plan that was initially approved by stockholders in 2012 and was amended and approved by the Board of Directors of the Company on September 23, 2021 and the stockholders on June 2, 2022 (the "Amended and Restated 2012 Purchase Plan"), under which 4.0 million shares of common stock were authorized. Shares are issued under the Amended and Restated 2012 Purchase Plan twice yearly at the end of each offering period and the number of shares that may be purchased by any participant during an offering period is limited to 5,000 shares. The first offering period of 2024 started on December 1, 2023 and will end on May 31, 2024. The second offering period of 2024 will begin on June 1, 2024 and will end on November 30, 2024. As of March 31, 2024, 1.3 million shares of common stock were available for issuance under the Amended and Restated 2012 Purchase Plan. Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the three months ended March 31, 2024 and 2023 are as follows: Three months ended (in millions) 2024 2023 Shares purchased under the plan — — Plan compensation expense $ 0.5 $ 0.5 Stock-Based Compensation Expense Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows: Three months ended (in millions) 2024 2023 Cost of testing revenue $ 0.3 $ 0.3 Research and development expense 1.2 0.6 Selling, general, and administrative expense 10.5 6.6 Total stock-based compensation expense $ 12.0 $ 7.5

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter. For the three months ended March 31, 2024, there was $0.1 million in income tax expense, or approximately (0.4)% of pre-tax loss, compared to an income tax expense of $2.1 million, or approximately (4.0)% of pre-tax loss, for the three months ended March 31, 2023. For the three months ended March 31, 2024, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to the recognition of valuation allowances. Due to the Company's cumulative loss and the exhaustion of future taxable income from the reversal of taxable temporary differences, the Company's estimated annual effective tax rate for the current year includes a valuation allowance against the majority of the current year increase in deferred tax assets. For the three months ended March 31, 2023, the Company’s effective tax rate differs from the U.S. federal statutory rate primarily due to the recognition of valuation allowances and uncertain tax positions.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws. The Company intends to defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows. The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability. As of March 31, 2024, except as noted below, the Company has not recorded any material accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, Contingencies. However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows. Further, in the event that damages from an unfavorable resolution of one or more of these proceedings exceed the aggregate amount of the coverage limits of the Company’s insurance, or if the Company’s insurance carriers disclaim coverage, the amounts payable by the Company could also have a material adverse impact on the Company’s results of operations, financial condition or cash flows. Stockholder Derivative Actions On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its former Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of the Company's current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations that were set forth in the securities class action lawsuit that was settled and then dismissed by the U.S. District Court for the District of Utah in December 2023 (the "Securities Class Action"), including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. On January 18, 2022, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the Securities Class Action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action. On April 19, 2024, the Court of Chancery ordered that Leo Shumacher be substituted for Ms. Kogus as a plaintiff in this consolidated action. On September 17, 2021, a stockholder derivative complaint was filed in the U.S. District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the Securities Class Action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the U.S. District Court for the District of Delaware pending the resolution of the securities class action lawsuit. On April 30, 2024, the parties across all of the foregoing stockholder derivative actions entered into a global stipulation of settlement to resolve the actions (the "Settlement"). On May 3, 2024, the parties submitted the Settlement to the Delaware Court of Chancery for approval. As part of the Settlement, (i) the Company agreed to adopt or implement certain corporate governance reforms; and (ii) the parties agreed that plaintiffs' counsel will apply to the court for an award of attorneys' fees and expenses not to exceed $950,000 to be paid by the Company, and that the Individual Defendants and the Company will not oppose or object to the requested fee award. The Settlement contains no admission of liability, wrongdoing or responsibility by any of the parties. The Settlement is subject to approval by the Delaware Court of Chancery. The Company has accrued $950,000 for the pending settlement of the foregoing stockholder derivative actions, which is included in Accrued Liabilities in the Company’s Condensed Consolidated Balance Sheet as of March 31, 2024. Other Legal Proceedings

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	3 Months Ended
	Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION The Company's supplemental cash flow information for the three months ended March 31, 2024 and March 31, 2023 are as follows: Three months ended (in millions) 2024 2023 Cash paid for income taxes $ — $ 0.3 Cash paid for interest 0.2 — Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ (0.3) $ 6.0 Operating lease liabilities (3.1) 6.0 Tenant improvement allowance not yet received — 2.7 Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities 4.5 8.0 The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows. Three months ended (in millions) 2024 2023 Cash and cash equivalents $ 96.9 $ 53.6 Restricted cash 8.7 9.5 Total cash, cash equivalents, and restricted cash $ 105.6 $ 63.1

LEASES

LEASES	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
LEASES	LEASES The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from approximately one Due to the increase in remote and hybrid work and the Company's need to ensure its facilities are designed to handle future growth, the Company has been executing on a multi-year strategy to reset its real estate footprint. As part of that strategy, during the three months ended March 31, 2023, the Company took full possession of the remaining phases of the west Salt Lake City facility and recognized an additional $5.9 million right-of-use asset and corresponding lease liability, net of tenant improvement allowance not yet received. Also during the three months ended March 31, 2023, the Company decided to cease the use of its corporate headquarters in Salt Lake City and transition corporate support operations to its new facility in west Salt Lake City, and as of December 31, 2023, the Company had formally assigned the lease for its previous corporate headquarters to a third party. During the three months ended March 31, 2024, the Company terminated the lease for one of its Salt Lake City facilities. As a result of the termination, the short-term lease liability of $3.1 million associated with the lease was removed from the Company's Condensed Consolidated Balance Sheets. The total net gain recognized associated with the termination of the lease was $1.2 million, which is included in Selling, general, and administrative expense in the Condensed Consolidated Statements of Operations. As of March 31, 2024, except as noted above, the Company expects to continue to occupy its existing facilities until the expiration of the leases.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE LOSS	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	ACCUMULATED OTHER COMPREHENSIVE LOSS The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders’ equity. The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions): Ending balance December 31, 2023 $ (3.7) Period translation adjustments (1.3) Reclassification of cumulative translation adjustment to income upon liquidation of an investment in a foreign entity 0.7 Ending balance March 31, 2024 $ (4.3)

ACQUISITION

ACQUISITION	3 Months Ended
	Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]
ACQUISITION	ACQUISITION On February 1, 2024, the Company acquired from Intermountain Health select assets for an immaterial amount from its Intermountain Precision Genomics ("IPG") laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah ("Precise acquisition"). In connection with the Precise acquisition, the Company recognized a gain of $2.2 million, which is included in Other income in the Company's Condensed Consolidated Statements of Operations.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENT On April 10, 2024, the Company amended the lease for its west Salt Lake City, Utah headquarters to include approximately 63,000 additional square feet in anticipation of future operating needs. The lease has a term of 12 years, which is expected to commence in fiscal year 2026. Total future rent payments for the additional space are approximately $18.2 million.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net loss	$ (26)	$ (54.7)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”).
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2023, the FASB issued accounting standards update ("ASU") 2023-07, which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company for annual reporting periods beginning after December 15, 2023 and for interim periods within fiscal years December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its segment disclosures. In December 2023, the FASB issued ASU 2023-09, which requires enhanced income tax disclosures, including disaggregation of information on the rate reconciliation table and disaggregated information related to income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its income tax disclosures.
Revenue	The Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, Precise Tumor, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results indicates transfer of control for revenue recognition purposes. Under ASC 606, Revenue from Contracts with Customers In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of the Company’s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Cash collections for certain tests delivered may differ from rates estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third-party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the quarter ended March 31, 2024, the Company recognized $3.0 million in revenue due to a retroactive coverage change by a payor for one of its prenatal products. Revenue recognized due to a change in estimate for tests in which the performance obligation was met in prior periods was immaterial. During the three months ended March 31, 2023, the impact of the amounts to be recognized for previously delivered tests was not material to the Company's Condensed Consolidated Statements of Operations.
Concentration of Credit Risk	Concentration of Credit Risk
Fair Value Measurements	The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration related to the acquisitions of Sividon Diagnostics GmbH ("Sividon") and Gateway Genomics, LLC ("Gateway"), the Company reassesses the fair value of each expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement periods of approximately 11.25 years and 1 year for Sividon and Gateway, respectively, utilizing various potential pay-out scenarios. Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business. The contingent consideration liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets. Changes to contingent consideration liabilities are reflected in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements.

REVENUE (Tables)

REVENUE (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Total Revenue by Type and by U.S versus Rest of World	The following table presents detail regarding the composition of the Company’s total revenue by product type and by geographical region, either U.S. or rest of world (“RoW”): Three months ended March 31, 2024 2023 (in millions) U.S. RoW Total U.S. RoW Total Testing revenues: Hereditary Cancer $ 76.3 $ 11.8 $ 88.1 $ 64.0 $ 11.7 $ 75.7 Tumor Profiling 23.9 7.0 30.9 28.8 8.5 37.3 Prenatal 44.1 0.2 44.3 36.0 0.2 36.2 Pharmacogenomics 38.9 — 38.9 32.0 — 32.0 Total revenue $ 183.2 $ 19.0 $ 202.2 $ 160.8 $ 20.4 $ 181.2

MARKETABLE INVESTMENT SECURIT_2

MARKETABLE INVESTMENT SECURITIES (Tables)	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for debt securities classified as available-for-sale securities by major security type and class of security at March 31, 2024 and December 31, 2023 were as follows: (in millions) Amortized Gross Gross Estimated March 31, 2024 Cash and cash equivalents: Cash $ 93.1 $ — $ — $ 93.1 Cash equivalents 3.8 — — 3.8 Total cash and cash equivalents 96.9 — — 96.9 Available-for-sale: Corporate bonds and notes 6.9 — (0.1) 6.8 Municipal bonds 0.6 — — 0.6 Federal agency issues — — — — Total $ 104.4 $ — $ (0.1) $ 104.3 (in millions) Amortized Gross Gross Estimated December 31, 2023 Cash and cash equivalents: Cash $ 129.9 $ — $ — $ 129.9 Cash equivalents 2.2 — — 2.2 Total cash and cash equivalents 132.1 — — 132.1 Available-for-sale: Corporate bonds and notes 8.4 — (0.1) 8.3 Municipal bonds 0.5 — — 0.5 Total $ 141.0 $ — $ (0.1) $ 140.9
Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at March 31, 2024: (in millions) Amortized Estimated Cash $ 93.1 $ 93.1 Cash equivalents 3.8 3.8 Available-for-sale: Due within one year 7.5 7.4 Total $ 104.4 $ 104.3

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis: (in millions) Level 1 Level 2 Level 3 Total March 31, 2024 Money market funds (a) $ 3.8 $ — $ — $ 3.8 Corporate bonds and notes 1.4 5.4 — 6.8 Municipal bonds — 0.6 — 0.6 Contingent consideration — — (5.4) (5.4) Total $ 5.2 $ 6.0 $ (5.4) $ 5.8 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. (in millions) Level 1 Level 2 Level 3 Total December 31, 2023 Money market funds (a) $ 2.2 $ — $ — $ 2.2 Corporate bonds and notes — 8.3 — 8.3 Municipal bonds — 0.5 — 0.5 Contingent consideration — — (5.4) (5.4) Total $ 2.2 $ 8.8 $ (5.4) $ 5.6 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest.
Schedule of Change in Fair Value of Contingent Consideration	The following table reconciles the change in the fair value of the contingent consideration during the periods presented: (in millions) Carrying Balance at December 31, 2023 $ (5.4) Change in fair value recognized in the Statements of Operations 0.2 Translation adjustments recognized in Other comprehensive loss (0.2) Ending balance at March 31, 2024 $ (5.4)

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	The property, plant and equipment at March 31, 2024 and December 31, 2023 were as follows: (in millions) March 31, December 31, Leasehold improvements $ 77.8 $ 91.3 Equipment 151.5 147.6 Property, plant and equipment, gross 229.3 238.9 Less accumulated depreciation (110.8) (119.9) Property, plant and equipment, net $ 118.5 $ 119.0 The Company recorded depreciation during the respective periods as follows: Three months ended (in millions) 2024 2023 Depreciation expense $ 4.9 $ 8.7

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the three months ended March 31, 2024 are as follows: (in millions) Total Beginning balance $ 287.4 Translation adjustments (0.4) Ending balance $ 287.0
Schedule of Amortizable Intangible Assets	The following summarizes the amounts reported as intangible assets: (in millions) Gross Accumulated Net At March 31, 2024 Developed technologies $ 625.4 $ (305.4) $ 320.0 Internal-use software 1.6 (0.3) 1.3 Internal-use software (in-process) 13.0 — 13.0 Customer relationships 1.6 (0.2) 1.4 Trademarks 6.1 (0.9) 5.2 Total intangible assets $ 647.7 $ (306.8) $ 340.9 (in millions) Gross Accumulated Net At December 31, 2023 Developed technologies $ 626.1 $ (295.3) $ 330.8 Internal-use software 0.8 (0.1) 0.7 Internal-use software (in-process) 11.2 — 11.2 Customer relationships 1.6 (0.2) 1.4 Trademarks 6.1 (0.7) 5.4 Total intangible assets $ 645.8 $ (296.3) $ 349.5
Schedule of Non-amortizable Intangible Assets	The following summarizes the amounts reported as intangible assets: (in millions) Gross Accumulated Net At March 31, 2024 Developed technologies $ 625.4 $ (305.4) $ 320.0 Internal-use software 1.6 (0.3) 1.3 Internal-use software (in-process) 13.0 — 13.0 Customer relationships 1.6 (0.2) 1.4 Trademarks 6.1 (0.9) 5.2 Total intangible assets $ 647.7 $ (306.8) $ 340.9 (in millions) Gross Accumulated Net At December 31, 2023 Developed technologies $ 626.1 $ (295.3) $ 330.8 Internal-use software 0.8 (0.1) 0.7 Internal-use software (in-process) 11.2 — 11.2 Customer relationships 1.6 (0.2) 1.4 Trademarks 6.1 (0.7) 5.4 Total intangible assets $ 645.8 $ (296.3) $ 349.5
Schedule of Recorded Amortization Expense for Intangible Assets	The Company recorded amortization expense during the respective periods for these intangible assets as follows: Three months ended (in millions) 2024 2023 Amortization of intangible assets $ 10.8 $ 10.7

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	The Company's accrued liabilities at March 31, 2024 and December 31, 2023 were as follows: (in millions) March 31, December 31, Employee compensation and benefits $ 37.8 $ 49.7 Accrued taxes payable 6.1 4.6 Refunds payable and reserves 19.1 20.1 Short-term contingent consideration 3.0 3.1 Accrued royalties 5.7 5.3 Legal settlement 6.0 6.0 Lease termination accrual 4.4 4.4 Other accrued liabilities 17.1 20.7 Total accrued liabilities $ 99.2 $ 113.9

OTHER LONG-TERM LIABILITIES (Ta

OTHER LONG-TERM LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2024
Other Liabilities Disclosure [Abstract]
Schedule of Other Long-Term Liabilities	The Company's other long-term liabilities at March 31, 2024 and December 31, 2023 were as follows: (in millions) March 31, December 31, Contingent consideration $ 2.4 $ 2.3 Escrow liability 7.5 7.5 Legal settlement 24.0 24.0 Other 6.7 7.5 Total other long-term liabilities $ 40.6 $ 41.3

PREFERRED AND COMMON STOCKHOL_2

PREFERRED AND COMMON STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Common Stock Issued and Outstanding	Shares of common stock issued and outstanding Three months ended (in millions) 2024 2023 Beginning common stock issued and outstanding 89.9 81.2 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan 0.6 0.3 Common stock issued and outstanding at end of period 90.5 81.5
Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations: Three months ended (in millions) 2024 2023 Denominator: Weighted-average shares outstanding used to compute basic EPS 89.9 81.3 Effect of dilutive shares — — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 89.9 81.3
Schedule of Potential Dilutive Common Shares	These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows: Three months ended (in millions) 2024 2023 Anti-dilutive options and RSUs excluded from EPS computation 6.3 5.6

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of the stock option activity for the three months ended March 31, 2024 is as follows: (number of shares in millions) Number Weighted Options outstanding at December 31, 2023 0.7 $ 13.38 Options outstanding at March 31, 2024 0.7 13.38 Options exercisable at March 31, 2024 0.5 $ 13.38
Schedule of Restricted Stock Unit Activity	A summary of the RSU awards activity under the Company’s equity plan and inducement awards, including PSU awards, for the three months ended March 31, 2024 is as follows: (number of shares in millions) Number Weighted RSUs unvested and outstanding at December 31, 2023 4.4 $ 24.37 RSUs granted 2.3 22.29 Less: RSUs vested (1.0) 25.18 RSUs canceled (0.1) 26.55 RSUs unvested and outstanding at March 31, 2024 5.6 $ 23.36
Schedule of Shares Purchased and Compensation Expense	Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the three months ended March 31, 2024 and 2023 are as follows: Three months ended (in millions) 2024 2023 Shares purchased under the plan — — Plan compensation expense $ 0.5 $ 0.5
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows: Three months ended (in millions) 2024 2023 Cost of testing revenue $ 0.3 $ 0.3 Research and development expense 1.2 0.6 Selling, general, and administrative expense 10.5 6.6 Total stock-based compensation expense $ 12.0 $ 7.5

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The Company's supplemental cash flow information for the three months ended March 31, 2024 and March 31, 2023 are as follows: Three months ended (in millions) 2024 2023 Cash paid for income taxes $ — $ 0.3 Cash paid for interest 0.2 — Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ (0.3) $ 6.0 Operating lease liabilities (3.1) 6.0 Tenant improvement allowance not yet received — 2.7 Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities 4.5 8.0
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows. Three months ended (in millions) 2024 2023 Cash and cash equivalents $ 96.9 $ 53.6 Restricted cash 8.7 9.5 Total cash, cash equivalents, and restricted cash $ 105.6 $ 63.1
Schedule of Restrictions on Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows. Three months ended (in millions) 2024 2023 Cash and cash equivalents $ 96.9 $ 53.6 Restricted cash 8.7 9.5 Total cash, cash equivalents, and restricted cash $ 105.6 $ 63.1

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Cumulative Translation Adjustments in Accumulated Other Comprehensive Loss	The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions): Ending balance December 31, 2023 $ (3.7) Period translation adjustments (1.3) Reclassification of cumulative translation adjustment to income upon liquidation of an investment in a foreign entity 0.7 Ending balance March 31, 2024 $ (4.3)

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	3 Months Ended
	Mar. 31, 2024 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reporting segments	1

REVENUE - Schedule of Total Rev

REVENUE - Schedule of Total Revenue by Type and by U.S versus Rest of World (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 202.2	$ 181.2
U.S.
Disaggregation of Revenue [Line Items]
Total revenue	183.2	160.8
RoW
Disaggregation of Revenue [Line Items]
Total revenue	19	20.4
Hereditary Cancer
Disaggregation of Revenue [Line Items]
Total revenue	88.1	75.7
Hereditary Cancer | U.S.
Disaggregation of Revenue [Line Items]
Total revenue	76.3	64
Hereditary Cancer | RoW
Disaggregation of Revenue [Line Items]
Total revenue	11.8	11.7
Tumor Profiling
Disaggregation of Revenue [Line Items]
Total revenue	30.9	37.3
Tumor Profiling | U.S.
Disaggregation of Revenue [Line Items]
Total revenue	23.9	28.8
Tumor Profiling | RoW
Disaggregation of Revenue [Line Items]
Total revenue	7	8.5
Prenatal
Disaggregation of Revenue [Line Items]
Total revenue	44.3	36.2
Prenatal | U.S.
Disaggregation of Revenue [Line Items]
Total revenue	44.1	36
Prenatal | RoW
Disaggregation of Revenue [Line Items]
Total revenue	0.2	0.2
Pharmacogenomics
Disaggregation of Revenue [Line Items]
Total revenue	38.9	32
Pharmacogenomics | U.S.
Disaggregation of Revenue [Line Items]
Total revenue	38.9	32
Pharmacogenomics | RoW
Disaggregation of Revenue [Line Items]
Total revenue	$ 0	$ 0

REVENUE - Narrative (Details)

REVENUE - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Revenue and Concentration Risk [Line Items]
Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments	$ 3,000,000
Capitalized costs incurred to obtain or fulfill contract	$ 0
Government Contracts Concentration Risk | Medicare | Revenues
Revenue and Concentration Risk [Line Items]
Concentration risk (percent)	12%	11%
Customer concentration | Medicare | Accounts receivable
Revenue and Concentration Risk [Line Items]
Concentration risk (percent)	15%		12%

MARKETABLE INVESTMENT SECURIT_3

MARKETABLE INVESTMENT SECURITIES - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Cash and cash equivalents:
Amortized cost	$ 96.9	$ 132.1	$ 53.6
Estimated fair value	96.9	132.1
Total
Amortized cost	104.4	141
Gross unrealized holding gains	0	0
Gross unrealized holding losses	(0.1)	(0.1)
Estimated fair value	104.3	140.9
Corporate bonds and notes
Available-for-sale:
Amortized cost	6.9	8.4
Gross unrealized holding gains	0	0
Gross unrealized holding losses	(0.1)	(0.1)
Estimated fair value	6.8	8.3
Municipal bonds
Available-for-sale:
Amortized cost	0.6	0.5
Gross unrealized holding gains	0	0
Gross unrealized holding losses	0	0
Estimated fair value	0.6	0.5
Federal agency issues
Available-for-sale:
Amortized cost	0
Gross unrealized holding gains	0
Gross unrealized holding losses	0
Estimated fair value	0
Cash
Cash and cash equivalents:
Amortized cost	93.1	129.9
Estimated fair value	93.1	129.9
Cash equivalents
Cash and cash equivalents:
Amortized cost	3.8	2.2
Estimated fair value	$ 3.8	$ 2.2

MARKETABLE INVESTMENT SECURIT_4

MARKETABLE INVESTMENT SECURITIES - Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Amortized cost
Cash and cash equivalents	$ 96.9	$ 132.1	$ 53.6
Available-for-sale, Due within one year	7.5
Amortized cost	104.4	141
Estimated fair value
Cash and cash equivalents	96.9	132.1
Available-for-sale, Due within one year	7.4
Estimated fair value	104.3	140.9
Cash
Amortized cost
Cash and cash equivalents	93.1	129.9
Estimated fair value
Cash and cash equivalents	93.1	129.9
Cash equivalents
Amortized cost
Cash and cash equivalents	3.8	2.2
Estimated fair value
Cash and cash equivalents	$ 3.8	$ 2.2

FAIR VALUE MEASUREMENTS - Narra

FAIR VALUE MEASUREMENTS - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Level 3 | Measurement Input, Expected Term | Sividon
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement period for earn out liability	11 years 3 months
Level 3 | Measurement Input, Expected Term | Gateway
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement period for earn out liability	1 year
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated fair value of long-term debt	$ 39.8

FAIR VALUE MEASUREMENTS - Sched

FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Financial Assets and Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 5.8	$ 5.6
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	3.8	2.2
Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	6.8	8.3
Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0.6	0.5
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	(5.4)	(5.4)
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	5.2	2.2
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	3.8	2.2
Level 1 | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	1.4	0
Level 1 | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 1 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	6	8.8
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 2 | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	5.4	8.3
Level 2 | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0.6	0.5
Level 2 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	(5.4)	(5.4)
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 3 | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 3 | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0	0
Level 3 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ (5.4)	$ (5.4)

FAIR VALUE MEASUREMENTS - Sch_2

FAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Reconciliation of change in fair value of contingent consideration
Beginning balance	$ (5.4)
Change in fair value recognized in the Statements of Operations	0.2
Translation adjustments recognized in Other comprehensive loss	(0.2)
Ending balance	$ (5.4)

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 229.3	$ 238.9
Less accumulated depreciation	(110.8)	(119.9)
Property, plant and equipment, net	118.5	119
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	77.8	91.3
Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 151.5	$ 147.6

PROPERTY, PLANT AND EQUIPMENT_4

PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Leasehold improvements
Property, Plant and Equipment [Line Items]
Accelerated depreciation	$ 5.7

PROPERTY, PLANT AND EQUIPMENT_5

PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Depreciation Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 4.9	$ 8.7

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 287.4
Translation adjustments	(0.4)
Ending balance	$ 287

GOODWILL AND INTANGIBLE ASSETS-

GOODWILL AND INTANGIBLE ASSETS- Schedule of Intangible Assets (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Gross Carrying Amount	$ 647.7
Accumulated Amortization	(306.8)	$ (296.3)
Net	340.9
Gross Carrying Amount, total		645.8
Net, total	340.9	349.5
Developed technologies
Intangible Assets [Line Items]
Gross Carrying Amount	625.4	626.1
Accumulated Amortization	(305.4)	(295.3)
Net	320	330.8
Internal-use software
Intangible Assets [Line Items]
Gross Carrying Amount	1.6	0.8
Accumulated Amortization	(0.3)	(0.1)
Net	1.3	0.7
Internal-use software (in-process)
Intangible Assets [Line Items]
Gross Carrying Amount	13	11.2
Accumulated Amortization	0	0
Net	13	11.2
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Amount	1.6	1.6
Accumulated Amortization	(0.2)	(0.2)
Net	1.4	1.4
Trademarks
Intangible Assets [Line Items]
Gross Carrying Amount	6.1	6.1
Accumulated Amortization	(0.9)	(0.7)
Net	$ 5.2	$ 5.4

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Schedule of Recorded Amortization Expense for Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 10.8	$ 10.7

ACCRUED LIABILITIES (Details)

ACCRUED LIABILITIES (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 37.8	$ 49.7
Accrued taxes payable	6.1	4.6
Refunds payable and reserves	19.1	20.1
Short-term contingent consideration	3	3.1
Accrued royalties	5.7	5.3
Legal settlement	6	6
Lease termination accrual	4.4	4.4
Other accrued liabilities	17.1	20.7
Total accrued liabilities	$ 99.2	$ 113.9

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details) - Line of Credit - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Oct. 31, 2023	Jun. 30, 2023
ABL Facility
Debt Instrument [Line Items]
Line of credit facility, commitment fee amount	$ 41,300,000
Revolving Credit Facility
Debt Instrument [Line Items]
Availability threshold amount	12,500,000
Revolving Credit Facility | ABL Facility
Debt Instrument [Line Items]
Maximum aggregate principal commitment				$ 90,000,000
Line of credit, increase in maximum principal upon request			$ 25,000,000
Increase principal commitment			$ 115,000,000
Long-term debt	40,000,000
Debt issuance costs	$ 1,300,000	$ 1,500,000
Line of credit facility, borrowing base, percent of eligible accounts receivable plus certain cash held	85%
Line of credit facility, borrowing base, eligible cash held	$ 20,000,000
Line of credit facility, borrowing base, eligible cash collections, period	60 days
Interest rate, weighted average percentage	8.71%
Debt instrument, covenant, liquidity amount, minimum	$ 60,000,000
Debt instrument, covenant, availability amount, minimum	$ 25,000,000
Fixed charge ratio, minimum	1
Line of credit facility, commitment fee amount	$ 10,600,000
Line of credit facility, commitment fee percentage	12.50%
Borrowing base period	30 days
Availability threshold amount	$ 12,500,000
Debt instrument, maximum amount borrowing base period	45 days
Revolving Credit Facility | ABL Facility | Minimum
Debt Instrument [Line Items]
Undrawn fee (percent)	0.375%
Availability threshold, percentage of maximum commitment amount	15%
Revolving Credit Facility | ABL Facility | Maximum
Debt Instrument [Line Items]
Undrawn fee (percent)	0.50%
Availability threshold, percentage of maximum commitment amount	15%
Revolving Credit Facility | ABL Facility | NYFRB | Variable Rate, Scenario One
Debt Instrument [Line Items]
Basis spread on rate (percent)	0.50%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Variable Rate, Scenario One
Debt Instrument [Line Items]
Basis spread on rate (percent)	1%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Variable Rate, Scenario Two
Debt Instrument [Line Items]
Basis spread on rate (percent)	0.10%
SOFR floor (percent)	0%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Minimum | Variable Rate, Scenario One
Debt Instrument [Line Items]
Basis spread on rate (percent)	1%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Minimum | Variable Rate, Scenario Two
Debt Instrument [Line Items]
Basis spread on rate (percent)	2%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Maximum | Variable Rate, Scenario One
Debt Instrument [Line Items]
Basis spread on rate (percent)	1.50%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Maximum | Variable Rate, Scenario Two
Debt Instrument [Line Items]
Basis spread on rate (percent)	2.50%
Revolving Credit Facility | ABL Facility | ABR Floor | Variable Rate, Scenario Two
Debt Instrument [Line Items]
SOFR floor (percent)	1%

OTHER LONG-TERM LIABILITIES - S

OTHER LONG-TERM LIABILITIES - Schedule of Other Long-Term Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Other Liabilities Disclosure [Abstract]
Contingent consideration	$ 2.4	$ 2.3
Escrow liability	7.5	7.5
Legal charges pending settlement	24	24
Other	6.7	7.5
Total other long-term liabilities	$ 40.6	$ 41.3

OTHER LONG-TERM LIABILITIES - N

OTHER LONG-TERM LIABILITIES - Narrative (Details) $ in Thousands	Oct. 23, 2023 USD ($) installment	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Legal charges pending settlement		$ 24,000	$ 24,000
Raygen, Inc vs. Myriad Women's Health, Inc.
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accrual, current		5,000
Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	$ 21,250
Number of annual installments | installment	5
Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | First Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	$ 5,000
Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | Second Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	5,000
Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | Third Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	5,000
Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | Fourth Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	5,000
Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | Final Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	1,250
Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Non-Contingent Payments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	$ 12,750
Number of annual installments | installment	3
Litigation settlement, outstanding		$ 7,750
Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Non-Contingent Payments | First Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	$ 5,000
Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Non-Contingent Payments | Second Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	$ 2,750

PREFERRED AND COMMON STOCKHOL_3

PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Narrative (Details) - $ / shares	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Preferred stock authorized (shares)	5,000,000
Preferred stock, par value (dollars per share)	$ 0.01
Preferred stock outstanding (shares)	0
Common stock authorized (shares)	150,000,000
Common stock, par value (dollars per share)	$ 0.01
Common stock issued (shares)	90,500,000	89,900,000	81,500,000	81,200,000
Common stock outstanding (shares)	90,500,000	89,900,000	81,500,000	81,200,000

PREFERRED AND COMMON STOCKHOL_4

PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Common Stock Issued and Outstanding (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Common shares issued and outstanding
Beginning common stock issued (shares)	89.9	81.2
Beginning common stock outstanding (shares)	89.9	81.2
Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan (shares)	0.6	0.3
Ending common stock issued (shares)	90.5	81.5
Ending common stock outstanding (shares)	90.5	81.5

PREFERRED AND COMMON STOCKHOL_5

PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Equity [Abstract]
Weighted-average shares outstanding used to compute basic EPS	89.9	81.3
Effect of dilutive shares	0	0
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS	89.9	81.3

PREFERRED AND COMMON STOCKHOL_6

PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Potential Dilutive Common Shares (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Equity [Abstract]
Anti-dilutive options and RSUs excluded from EPS computation (shares)	6.3	5.6

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) $ in Millions		3 Months Ended
	Sep. 23, 2021 shares	Mar. 31, 2024 USD ($) day shares	Jun. 01, 2023 shares
Share-Based Compensation [Line Items]
Unrecognized stock-based compensation expense related to stock options | $		$ 0.3
Options granted (in shares)		0
2017 Plan
Share-Based Compensation [Line Items]
Shares available for grant (shares)		2,500,000	4,800,000
2012 Purchase Plan
Share-Based Compensation [Line Items]
Number of additional shares authorized (shares)	4,000,000
Maximum number of shares per participant per offering period (shares)	5,000
Shares issued under the plan (shares)		1,300,000
Options and RSUs | Non-Employee Director
Share-Based Compensation [Line Items]
Service period for award vesting (in years)		1 year
RSUs
Share-Based Compensation [Line Items]
Vesting rights, average trading days | day		20
Weighted-average period for recognition (in years)		2 years 6 months
Unrecognized stock-based compensation expense related to RSUs | $		$ 104.2
RSUs | Minimum
Share-Based Compensation [Line Items]
Service period for award vesting (in years)		3 years
RSUs | Maximum
Share-Based Compensation [Line Items]
Service period for award vesting (in years)		4 years
RSUs | Achievement Levels Based on EPS Targets
Share-Based Compensation [Line Items]
Vesting weight (percent)		34%
RSUs | Relative Total Stockholders Return
Share-Based Compensation [Line Items]
Vesting weight (percent)		33%
RSUs | Performance Based on Nasdaq Healthcare Provider Index
Share-Based Compensation [Line Items]
Vesting weight (percent)		33%
Stock Options
Share-Based Compensation [Line Items]
Weighted-average period for recognition (in years)		4 months 24 days

STOCK-BASED COMPENSATION - Sche

STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - $ / shares shares in Millions	Mar. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Options outstanding (in shares)	0.7	0.7
Options exercisable at end of period (shares)	0.5
Options outstanding (dollars per share)	$ 13.38	$ 13.38
Options exercisable at end of period (dollars per share)	$ 13.38

STOCK-BASED COMPENSATION - Sc_2

STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details) - RSUs shares in Millions	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Number of Shares
RSUs unvested and outstanding, beginning balance (shares) | shares	4.4
RSUs granted (shares) | shares	2.3
RSUs vested (shares) | shares	(1)
RSUs canceled (shares) | shares	(0.1)
RSUs unvested and outstanding, ending balance (shares) | shares	5.6
Weighted Average Grant Date Fair Value
RSUs unvested and outstanding, beginning balance (dollars per share) | $ / shares	$ 24.37
RSUs granted (dollars per share) | $ / shares	22.29
RSUs vested (dollars per share) | $ / shares	25.18
RSUs canceled (dollars per share) | $ / shares	26.55
RSUs unvested and outstanding, ending balance (dollars per share) | $ / shares	$ 23.36

STOCK-BASED COMPENSATION - Sc_3

STOCK-BASED COMPENSATION - Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity (Details) - 2012 Purchase Plan - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation [Line Items]
Shares purchased under the plan	0	0
Plan compensation expense	$ 0.5	$ 0.5

STOCK-BASED COMPENSATION - Sc_4

STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	$ 12	$ 7.5
Cost of testing revenue
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	0.3	0.3
Research and development expense
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	1.2	0.6
Selling, general, and administrative expense
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	$ 10.5	$ 6.6

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 0.1	$ 2.1
Approximate tax rate	(0.40%)	(4.00%)

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	May 03, 2024	Mar. 31, 2024	Dec. 31, 2023
Loss Contingencies [Line Items]
Pending settlement accrued		$ 6,000,000	$ 6,000,000
Pending Litigation
Loss Contingencies [Line Items]
Pending settlement accrued		$ 950,000
Pending Litigation | Subsequent Event | Maximum
Loss Contingencies [Line Items]
Settlement agreement	$ 950,000

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Cash paid for income taxes	$ 0	$ 0.3
Cash paid for interest	0.2	0
Change in operating lease right-of-use assets and lease liabilities
Operating lease right-of-use assets	(0.3)	6
Operating lease liabilities	(3.1)	6
Tenant improvement allowance not yet received	0	2.7
Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities	$ 4.5	$ 8

SUPPLEMENTAL CASH FLOW INFORM_4

SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Cash and cash equivalents	$ 96.9	$ 132.1	$ 53.6
Restricted cash	8.7		9.5
Total cash, cash equivalents, and restricted cash	$ 105.6	$ 140.9	$ 63.1	$ 66.4

LEASES (Details)

LEASES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 58.9		$ 61.6
Short term lease liability	3.1
Gain on termination of lease	3.1	$ 0
Selling, general, and administrative expense
Lessee, Lease, Description [Line Items]
Gain on termination of lease	$ 1.2
West Salt Lake City
Lessee, Lease, Description [Line Items]
Operating lease liability		5.9
Operating lease right-of-use assets		$ 5.9
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms (in years)	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms (in years)	15 years

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 783.2	$ 885.8
Period translation adjustments	(0.5)	1.5
Reclassification of cumulative translation adjustment to income upon liquidation of an investment in a foreign entity	(0.7)	0
Ending balance	760	$ 835.2
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(3.7)
Period translation adjustments	(1.3)
Reclassification of cumulative translation adjustment to income upon liquidation of an investment in a foreign entity	0.7
Ending balance	$ (4.3)

ACQUISITION (Details)

ACQUISITION (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Gain on acquisition	$ 2.2	$ 0

SUBSEQUENT EVENT (Details)

SUBSEQUENT EVENT (Details) - Subsequent Event ft² in Thousands, $ in Millions	May 07, 2024 USD ($)	Apr. 10, 2024 USD ($) ft²
Disposed of by Sale | EndoPredict
Subsequent Event [Line Items]
Proceeds from sale of business	$ 10
West Salt Lake City
Subsequent Event [Line Items]
Area of real estate property | ft²		63
Lease term (in years)		12 years
Lease payments due		$ 18.2